Any combinations found to be more or less effective? And then lastly, what about safety?

Yeah.

So I think the general consensus is that, you know, that they are efficacious, right? And I don't think that you are going, that there's any...

there's a lot of question asked towards why that would make sense, right? You're again, synergistically hitting on two different forms of the inflammatory cascade that can be targeting the intestinal system, or again, outside of the intestinal system, if there's extra intestinal manifestations.

So I think that the data that exists right now, you show that we've got improvements.

And I would say, and we've kind of touched on this, the data really shows that we're seeing the best improvements in the individuals who have had refractory disease.

And by that, I mean, have been on previous degrees of advanced therapies, whether or not it's a biologic or a small molecule.

So Jen, what are we learning now from clinical trials on combination therapy? So exciting data presented at DDW.